Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Journal: The Prostate
Published: February 26, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: February 08, 2024
Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Journal: Expert opinion on investigational drugs
Published: October 07, 2023
Chemical modulation of Schistosoma mansoni lysine specific demethylase 1 (SmLSD1) induces wide-scale biological and epigenomic changes.
Journal: Wellcome open research
Published: March 10, 2023
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
Journal: Blood advances
Published: February 23, 2023
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 08, 2022
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.
Journal: Haematologica
Published: March 22, 2021
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Journal: Cancer discovery
Published: December 13, 2019
Last Updated: 09/26/2026